Citations

Clear

5 citation(s) found for "Kis, Béla".

Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey
Akgül, Mahmut , Ertoy, Dilek, Argani, Pedram , Gupta, Sounak , Reuter, Victor E. , Tickoo, Satish K. , Netto, George J. , Hes, Ondřej , Hirsch, Michelle S. , Delahunt, Brett , Mehra, Rohit , Skala, Stephanie L. , Osunkoya, Adeboye O. , Harik, Lara R. , Nourieh, Maya , Zynger, Debra L. , Smith, Steven Cristopher, Nazeer, Tipu, Kulaç, İbrahim , Khani, Francesca , Tretiakova, Maria , Vakar‐Lopez, Funda , Barkan, Güliz A. , Molinié, Vincent , Verkarre, Virginie , Rao, Qiu , Kis, Lóránd, Panizo, Ángel , Farzaneh, Ted , Magers, Martin J. , Sanfrancesco, Joseph, Perrino, Carmen M. , Gondim, Dibson , Araneta, Ronald, So, Jeffrey , Ro, Jae Y. , Wasco, Matthew J., Hameed, Omar , Wobker, Sara E. , Melamed, Jonathan , Cheng, Liang , Idrees, Muhammad T. , Gumuskaya, Berrak , Samaratunga, Hemamali , Cheng, Liang , Skala, Stephanie L , Tretiakova, Maria S , Williamson, Sean R. , Caliò, Anna , Al-Ahmadie, Hikmat A , Rao, Priya , Sangoi, Ankur R. , López-Beltrán, Antonio , Samaratunga, Hemamali

Mayo Clinic

Journal of Clinical Pathology | January 29, 2021 | Volume: 74 | Issue: 5 | Pages: 291-299

10.1136/jclinpath-2020-207372 | PMID 33514585 Get It

Transcription factor E3-rearranged renal cell carcinoma (TFE3-RCC) has heterogenous morphologic and immunohistochemical (IHC) features. 131 pathologists with genitourinary expertise were invited in an online survey containing 23 questions assessing their experience on TFE3-RCC diagnostic work-up. Fifty (38%) participants completed the survey. 46 of 50 participants reported multiple patterns, most commonly papillary pattern (almost always 9/46, 19.5%; frequently 29/46, 63%). Large epithelioid cells with abundant cytoplasm were the most encountered cytologic feature, with either clear (almost always 10/50, 20%; frequently 34/50, 68%) or eosinophilic (almost always 4/49, 8%; frequently 28/49, 57%) cytology. Strong (3+) or diffuse (>75% of tumour cells) nuclear TFE3 IHC expression was considered diagnostic by 13/46 (28%) and 12/47 (26%) participants, respectively. Main TFE3 IHC issues were the low specificity (16/42, 38%), unreliable staining performance (15/42, 36%) and background staining (12/42, 29%). Most preferred IHC assays other than TFE3, cathepsin K and pancytokeratin were melan A (44/50, 88%), HMB45 (43/50, 86%), carbonic anhydrase IX (41/50, 82%) and CK7 (32/50, 64%). Cut-off for positive TFE3 fluorescent in situ hybridisation (FISH) was preferably 10% (9/50, 18%), although significant variation in cut-off values was present. 23/48 (48%) participants required TFE3 FISH testing to confirm TFE3-RCC regardless of the histomorphologic and IHC assessment. 28/50 (56%) participants would request additional molecular studies other than FISH assay in selected cases, whereas 3/50 participants use additional molecular cases in all cases when TFE3-RCC is in the differential. Optimal diagnostic approach on TFE3-RCC is impacted by IHC and/or FISH assay preferences as well as their conflicting interpretation methods.
Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Parikh, Neehar D. , Roberts, Lewis R. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Valle, Juan W. , Valle, Juan W , Roberts, Lewis R , Parikh, Neehar D , Bridgewater, John , Roberts, Rebecca, Salem, Riad , Sicklick, Jason Keith

Mayo Clinic

Cancers | August 21, 2020 | Volume: 12 | Issue: 9 | Pages: 2375

10.3390/cancers12092375 | PMID 32825784 Get It

Background: Patients with cholangiocarcinoma often have indwelling biliary stents or catheters which are prone to obstructions and/or infections; studies show that 20–40% present with fever and/or jaundice requiring urgent treatment in the outpatient setting for which there are no uniform guidelines. The goal was to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: Thirteen expert physicians from relevant specialties, geography, and practice settings were recruited for the panel. Patient scenarios were developed and panelists rated the therapies before and after a face-to-face discussion. The appropriateness of various therapies was rated on a scale from 1–9 and classified as appropriate, inappropriate, or uncertain. Scenarios with greater than 2 (>2) ratings of 1–3 (inappropriate) and greater than 2 (>2) ratings of 7–9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions and the UK (8%) and had practiced for a mean 16.5 years (4–33 years). Panelists rated 480 scenarios before the meeting and re-rated 288 of the clinical scenarios after the meeting. The panelists agreed that ongoing treatment with chemotherapy did not influence decision-making and, therefore, 192 scenarios were excluded from the final list. Disagreement decreased from 37.5% before to 10.4% after the meeting. Consensus on stent/tube manipulation and inpatient antibiotic therapy was obtained and summarized in patients as “appropriate” or “maybe appropriate” based on a patient’s bilirubin level at presentation. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in the urgent management of ascending cholangitis in patients with cholangiocarcinoma.
The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma.
Moser, Justin C. , Pulido, José S. , Dronca, Roxana , Markovic, Svetomir, Markovic, Svetomir N. , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e20011-e20011

10.1200/jco.2014.32.15_suppl.e20011 Get It

Guidelines for management of urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Roberts, Lewis R. , Parikh, Neehar D. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Roberts, Lewis R , Parikh, Neehar D , Bridgewater, John , Roberts, Rebecca, Sicklick, Jason Keith , Valle, Juan W.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: e15641-e15641

10.1200/jco.2017.35.15_suppl.e15641 Get It

e15641 Background: CC pts with biliary stents or catheters are prone to have obstruction/infection and studies show 20-40% present with fever/or jaundice requiring urgent treatment for which there is no uniform guideline. We aimed to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: We recruited 13 physician experts from relevant specialty, geography, and practice settings. Patient scenarios were developed and panelists rated the therapies before and after a face-to-face discussion. The appropriateness of various therapies was rated on a 1-9 scale and classified as appropriate, inappropriate, or uncertain. Scenarios with > 2 ratings of 1-3 (inappropriate) and > 2 ratings of 7-9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions (92%) and the UK (8%); had practiced for a mean 16.5 years (4-33 years). Panelists rated 480 scenarios before the meeting, but re-rated only 288 clinical scenarios as they felt that ongoing treatment with chemotherapy did not influence decision-making. Disagreement decreased from 37.5% before the meeting to 10.4% after. Consensus statements are summarized in the table below. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in urgent management of ascending cholangitis in pts with CC. (Support: The Cholangiocarcinoma Foundation). [Table: see text]
Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.
Iyer, Renuka , Acquisto, Susan, Choti, Michael A., Hong, Theodore S. , Kis, Béla , Mead, Peter A., Parikh, Neehar D. , Roberts, Lewis R. , Siegel, Richard S., Whisenant, Jonathan, Cherepanov, Dasha , Broder, Michael S. , Bridgewater, John , Roberts, Rebecca J. , Sicklick, Jason Keith , Valle, Juan W. , Roberts, Lewis R , Parikh, Neehar D

Mayo Clinic

Journal of Clinical Oncology | March 21, 2017 | Volume: 35 | Issue: 4_suppl | Pages: 452-452

10.1200/jco.2017.35.4_suppl.452 Get It

452 Background: CC pts with biliary stents or catheters often present with fever and/or jaundice requiring urgent treatment for which there is no uniform guideline. We aimed to develop an expert panel consensus on this topic using the modified RAND/UCLA Delphi process to rate treatment appropriateness. Methods: We recruited 13 physician experts from relevant specialty, geography, and practice settings. Patient scenarios were developed based on a literature review, and therapies were rated by the experts before and after a face-to-face discussion. The appropriateness of various therapies was rated on a 1-9 scale and classified as appropriate, inappropriate, or uncertain. Scenarios with > 2 ratings of 1-3 (inappropriate) and > 2 ratings of 7-9 (appropriate) were considered to have disagreement and were not assigned an appropriateness rating. Results: Panelists were from all US regions (92%) and the UK (8%); had practiced for a mean 16.5 years (4-33 years) and reported seeing an average of 120 unique CC patients a year (0-900 pts). Panelists rated 288 clinical scenarios. Experts decided that ongoing treatment with chemotherapy did not influence decision-making. Disagreement decreased from 37.5% before the meeting to 10.4% after. Consensus statements are summarized in table 1. Conclusions: The Delphi process produced consensus guidelines to fill an unmet need in urgent management of ascending cholangitis in pts with CC. Studies of the impact of these guidelines on cost of care and pt outcomes are warranted. (Support: The Cholangiocarcinoma Foundation)[Table: see text]